What's Going On With Tharimmune Shares Monday?
What's Going On With Tharimmune Shares Monday?
"We look forward to initiating a Phase 2 multiple-ascending dose trial in the coming months to evaluate TH104 in chronic pruritus in primary biliary cholangitis (PBC) patients, with topline data expected in 2025. In the meantime, we continue to engage with both U.S. and EU regulatory authorities," said Tharimmune, Inc. (NASDAQ:THAR) shares initially traded higher on Monday, but have since reversed after the company presented clinical data at the 75th American Association for the Study of Liver Disease (AASLD) meeting. Here's what you need to know.
Tharimmune, Inc.（納斯達克：THAR）股票週一最初交易上漲，但在公司在第75屆美國肝病研究協會（AASLD）會議上呈現臨床數據後已回落。以下是您需要了解的內容。
What To Know: Tharimmune, a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, presented positive clinical data from a Phase I trial of TH104, a potential treatment for chronic pruritus in chronic liver disease.
Tharimmune是一家處於臨床階段的生物技術公司，正在開發一系列用於炎症和免疫學的治療候選藥物，呈現了TH104的I期試驗的積極臨床數據，這是一種用於慢性肝病中慢性瘙癢的潛在治療。
The clinical data showed that higher levels of TH104 in the blood were associated with a reduction in itching, a common symptom of chronic pruritus. The treatment also appeared safe, with no serious side effects reported.
臨床數據表明，血液中較高水平的TH104與瘙癢的減輕有關，而瘙癢是慢性瘙癢的常見症狀。該治療似乎也很安全，沒有報告嚴重副作用。
"We look forward to initiating a Phase 2 multiple-ascending dose trial in the coming months to evaluate TH104 in chronic pruritus in primary biliary cholangitis (PBC) patients, with topline data expected in 2025. In the meantime, we continue to engage with both U.S. and EU regulatory authorities," said Randy Milby, CEO of Tharimmune.
「我們期待在接下來的幾個月內啓動針對原發性膽汁性膽管炎（PBC）患者慢性瘙癢的II期多升劑量試驗，預期在2025年獲得總結數據。與此同時，我們將繼續與美國和歐盟監管機構進行接觸，」Tharimmune首席執行官Randy Milby說道。
How To Buy THAR Shares
如何購買THAR股票
By now you're likely curious about how to participate in the market for Tharimmune – be it to purchase shares, or even attempt to bet against the company.
現在您可能好奇如何參與Tharimmune的市場——無論是購買股票，還是嘗試對抗該公司。
Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy 'fractional shares,' which allows you to own portions of stock without buying an entire share.
購買股票通常通過券商帳戶完成。您可以在這裏找到可能的交易平台列表。許多平台允許您購買「碎股」，這使您無需購買整股就可以擁有部分股票。
In the case of Tharimmune, which is trading at $1.93 as of publishing time, $100 would buy you 51.81 shares of stock.
就Tharimmune而言，截至出版時交易價格爲1.93美元，100美元將爲您購買到51.81股股票。
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to 'go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.
如果您想押注股票下跌，流程就更爲複雜了。您需要訪問期權交易平台，或者找一家券商讓您通過借出股票進行「開空」操作（借股出售）。您可以在該資源中了解到賣空股票的過程。否則，如果您的券商允許您交易期權，您可以在當前股票交易價以上的執行價上購買看跌期權或者賣出看漲期權 - 無論哪種情況都可以讓您從股票價格下跌中獲利。
THAR Price Action: At the time of publication, Tharimmune shares were down 8.29% at $1.99, according to data from Benzinga Pro.
THAR價格走勢：根據Benzinga Pro的數據，在發佈時，Tharimmune的股價下跌了8.29%，報1.99美元。
Image: Photo by roberto-sorin for Unsplash
圖片：由roberto-sorin提供的Unsplash
譯文內容由第三人軟體翻譯。
